Breaking News Instant updates and real-time market news.

ETON

Eton Pharmaceuticals

$5.69

0.095 (1.70%)

07:04
08/19/19
08/19
07:04
08/19/19
07:04

Eton Pharmaceuticals announces results from bioequivalence studies of ET-104

Eton Pharmaceuticals announced results from bioequivalence studies of ET-104, Eton's proprietary oral liquid formulation of a molecule frequently used to treat a severe neurological condition. In bioequivalence studies conducted in 35 human subjects under both fed and fasting conditions, ET-104 demonstrated pharmacokinetic equivalence to a currently FDA-approved oral solid product of the same active ingredient. The 90% confidence intervals for ET-104's area-under-the-curve and peak concentration measurements were within the 80%-125% range that is commonly used to define bioequivalence. Based on these trial results, Eton anticipates submitting an new drug application with the FDA for the product in Q4.

  • 17

    Mar

ETON Eton Pharmaceuticals
$5.69

0.095 (1.70%)

06/21/19
HCWC
06/21/19
NO CHANGE
Target $18
HCWC
Buy
Eton Pharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Eton Pharmaceuticals to $18 from $15 after the company in-licensed ET-105, a patent-pending formulation of lamotrigine designed to be delivered to patients as an oral liquid, from the privately-held Aucta Pharmaceuticals. The analyst believes the in-licensing of ET-105 meaningfully expands Eton's "stable" of neurology-focused product candidates. He reiterates a Buy rating on the shares.
07/15/19
WELS
07/15/19
NO CHANGE
Target $9
WELS
Underperform
Wells says Bausch contribution from EM-100 likely has to come out of guidance
After Eton Pharmaceuticals (ETON) announced on Friday night that partner Bausch Health (BHC) received a Complete Response Letter related to the application for EM-100, an investigational treatment of itchy eyes that Bausch acquired the rights for in February of this year, Wells Fargo analyst David Maris noted that Bausch has not issued a press release or an update related to this CRL and that he has not yet heard back from the company after having reached out for comment. This setback is likely to push the timeline back and any contribution that might have been in 2019 guidance will have to come out, said Maris, who noted that the deal and the potential product "appear to be small." Maris maintains an Underperform rating on Bausch Health shares.
07/17/19
HCWC
07/17/19
NO CHANGE
Target $18
HCWC
Buy
Eton Pharmaceuticals 15% selloff since CRL unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju views the 15% selloff this week after Eton Pharmaceuticals (ETON) said it received a Complete Response Letter from the FDA on EM-100 as unwarranted. EM-100 is an "extremely minor contributor" to Eton's overall value proposition, since it is destined to be an over-the-counter product in a commodity segment, Selvaraju tells investors in a research note. Further, the CRL did not cite any issues with clinical data, and Bausch Health (BHC) has not wavered in its support of the drug, adds the analyst. He believes that any remaining items to be resolved are probably solely laboratory test-related in nature, which should be addressable within two to three months. Selvaraju views the recent selloff as a buying opportunity and reiterates a Buy rating on Eton Pharmaceuticals with an $18 price target.
08/05/19
LSCM
08/05/19
INITIATION
Target $15
LSCM
Buy
Eton Pharmaceuticals initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil started Eton Pharmaceuticals with a Buy rating and $15 price target. The company has a "diversified" pipeline of 12 product candidates in various stages of development which are targeting a number of therapeutic areas, O'Neil tells investors in a research note. The analyst sees the potential for $69M of revenue from the first three of the 12 products in its pipeline. Further, he believes Eton's management team has a track record of successfully growing businesses through "value-creating business development activities."

TODAY'S FREE FLY STORIES

NMM

Navios Maritime Partners

$17.92

-0.27 (-1.48%)

06:30
09/20/19
09/20
06:30
09/20/19
06:30
Initiation
Navios Maritime Partners initiated  »

Navios Maritime Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$15.09

0.67 (4.65%)

06:29
09/20/19
09/20
06:29
09/20/19
06:29
Syndicate
Breaking Syndicate news story on SunPower »

SunPower files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$40.11

-0.73 (-1.79%)

, PM

Philip Morris

$71.70

0.12 (0.17%)

06:28
09/20/19
09/20
06:28
09/20/19
06:28
Periodicals
Illicit vaping products end up online, WSJ says »

Daniela Hernandez of the…

MO

Altria Group

$40.11

-0.73 (-1.79%)

PM

Philip Morris

$71.70

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$51.58

-0.15 (-0.29%)

, AMD

AMD

$30.27

-0.16 (-0.53%)

06:27
09/20/19
09/20
06:27
09/20/19
06:27
Recommendations
Intel, AMD, Western Digital, Micron, Nvidia analyst commentary  »

Mizuho checks indicate…

INTC

Intel

$51.58

-0.15 (-0.29%)

AMD

AMD

$30.27

-0.16 (-0.53%)

WDC

Western Digital

$62.64

-0.9 (-1.42%)

MU

Micron

$49.82

-0.67 (-1.33%)

NVDA

Nvidia

$176.91

-3.09 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 24

    Oct

  • 07

    Nov

TCP

TC PipeLines

$40.82

0.09 (0.22%)

06:26
09/20/19
09/20
06:26
09/20/19
06:26
Upgrade
TC PipeLines rating change  »

TC PipeLines upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUMRF

Hummingbird

$0.00

(0.00%)

06:21
09/20/19
09/20
06:21
09/20/19
06:21
Initiation
Hummingbird initiated  »

Hummingbird initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$9.30

-0.01 (-0.11%)

06:21
09/20/19
09/20
06:21
09/20/19
06:21
Initiation
Xenon Pharmaceuticals initiated  »

Xenon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ADDYY

Adidas

$0.00

(0.00%)

06:20
09/20/19
09/20
06:20
09/20/19
06:20
Initiation
Adidas initiated  »

Adidas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$128.67

-3.065 (-2.33%)

06:20
09/20/19
09/20
06:20
09/20/19
06:20
Initiation
Berenberg starts Wayfair with Sell rating on intensifying competition »

Berenberg analyst Graham…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$59.08

-0.63 (-1.06%)

06:20
09/20/19
09/20
06:20
09/20/19
06:20
Recommendations
Square analyst commentary  »

Square price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

  • 06

    Nov

FB

Facebook

$190.15

1.96 (1.04%)

06:19
09/20/19
09/20
06:19
09/20/19
06:19
Periodicals
Zuckerberg meets with Trump with Facebook on the defense, Bloomberg says »

Naomi Nix, Rebecca Kern,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

ATO

Atmos Energy

$112.30

0.49 (0.44%)

06:18
09/20/19
09/20
06:18
09/20/19
06:18
Initiation
Atmos Energy initiated  »

Atmos Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FE

FirstEnergy

$48.10

0.01 (0.02%)

06:17
09/20/19
09/20
06:17
09/20/19
06:17
Downgrade
FirstEnergy rating change  »

FirstEnergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

NFLX

Netflix

$286.58

-4.97 (-1.70%)

06:17
09/20/19
09/20
06:17
09/20/19
06:17
Periodicals
Netflix CEO plans to make 'big increase' in buying U.K. content, Reuters reports »

Netflix plans to make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 16

    Oct

GL

Globe Life

$94.34

-0.59 (-0.62%)

06:15
09/20/19
09/20
06:15
09/20/19
06:15
Initiation
Globe Life initiated  »

Globe Life initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$220.91

-1.8 (-0.81%)

06:14
09/20/19
09/20
06:14
09/20/19
06:14
Recommendations
Apple analyst commentary  »

Apple's new iPhone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$8.19

0.04 (0.49%)

06:12
09/20/19
09/20
06:12
09/20/19
06:12
Upgrade
Ericsson rating change  »

Ericsson upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

STX

Seagate

$52.85

-3.89 (-6.86%)

06:12
09/20/19
09/20
06:12
09/20/19
06:12
Recommendations
Seagate analyst commentary  »

Seagate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$51.58

-0.15 (-0.29%)

06:12
09/20/19
09/20
06:12
09/20/19
06:12
Periodicals
Intel increasing EUV equipment, material purchases, DigiTimes reports »

Intel has started placing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

AMZN

Amazon.com

$1,822.21

4.21 (0.23%)

06:10
09/20/19
09/20
06:10
09/20/19
06:10
Periodicals
Amazon CEO announces goal to be carbon neutral by 2040, CNBC reports »

Amazon CEO Jeff Bezos has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

RAMP

LiveRamp

$46.44

0.43 (0.93%)

06:10
09/20/19
09/20
06:10
09/20/19
06:10
Upgrade
LiveRamp rating change  »

LiveRamp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCP

TC PipeLines

06:07
09/20/19
09/20
06:07
09/20/19
06:07
Upgrade
TC PipeLines rating change  »

TC PipeLines upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPAM

Epam Systems

$185.46

0.86 (0.47%)

06:07
09/20/19
09/20
06:07
09/20/19
06:07
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$190.15

1.96 (1.04%)

06:06
09/20/19
09/20
06:06
09/20/19
06:06
Periodicals
Person dies by suicide at Facebook headquarters in Menlo Park, BI reports »

A Facebook employee has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

CTSH

Cognizant

$63.44

-0.07 (-0.11%)

06:06
09/20/19
09/20
06:06
09/20/19
06:06
Initiation
Cognizant initiated  »

Cognizant initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.